HOOKIPA Pharma has been given more time to decide whether to make a firm offer for Poolbeg Pharma PLC (AIM:POLB). The so-called put-up-or-shut-up (PUSUS) deadline of January 30 has been extended to February 27 to allow more time for due diligence and discussions. HOOKIPA and Poolbeg have been in talks over an all-share deal to create a stronger biopharmaceutical company focused on immunotherapies for cancer and other serious diseases. Gilead Sciences has signalled support for the deal and may invest up to $8.75 million.
The Markets by Proactive
Go to Proactive Australia
Proactive’s Australian coverage continues on .com